Gastroenterology and Hepatology

Episodes 1-16 of 32

Improving Adherence to CRC Screening: A Primary Care Physician’s Guide
Improving Adherence to CRC Screening: A Primary Care Physician’s Guide
Clinician's Roundtable
Improving Adherence to CRC Screening: A Primary Care Physician’s Guide
- Charles Turck, PharmD, BCPS, BCCCP
- Sara Enslin, PA
Optimizing HCC Screening: Strategies to Overcome Common Barriers
Optimizing HCC Screening: Strategies to Overcome Common Barriers
Project Oncology®
Optimizing HCC Screening: Strategies to Overcome Common Barriers
- Hannah Lee, MD
Enhancing HCC Outcomes Through Multidisciplinary Care
Enhancing HCC Outcomes Through Multidisciplinary Care
Project Oncology®
Enhancing HCC Outcomes Through Multidisciplinary Care
- Charles Turck, PharmD, BCPS, BCCCP
- Hannah Lee, MD
Delivering Guideline-Based Hepatocellular Carcinoma Care with an Interactive Tool
Delivering Guideline-Based Hepatocellular Carcinoma Care with an Interactive Tool
Project Oncology®
Delivering Guideline-Based Hepatocellular Carcinoma Care with an Interactive Tool
- Jody Takemoto, PhD
- Robert Wong, MD
Dual Challenges: Managing Hepatocellular Carcinoma with Hepatitis B Co-Infection
Dual Challenges: Managing Hepatocellular Carcinoma with Hepatitis B Co-Infection
Project Oncology®
Dual Challenges: Managing Hepatocellular Carcinoma with Hepatitis B Co-Infection
- Jody Takemoto, PhD
- Robert Wong, MD
Uncovering Barriers to HCC Surveillance in Patients with Cirrhosis
Uncovering Barriers to HCC Surveillance in Patients with Cirrhosis
Project Oncology®
Uncovering Barriers to HCC Surveillance in Patients with Cirrhosis
- Jody Takemoto, PhD
- Robert Wong, MD
Practice Changing Highlights in G/GEJ Cancers: The Latest Data from Chicago
Practice Changing Highlights in G/GEJ Cancers: The Latest Data from Chicago
MinuteCE®
Practice Changing Highlights in G/GEJ Cancers: The Latest Data from Chicago
1.25 program credits
- Samuel J. Klempner, MD
1.25 program credits
Hepatocellular Carcinoma: Examining Its Prevalence and Prognostic Biomarkers
Hepatocellular Carcinoma: Examining Its Prevalence and Prognostic Biomarkers
Project Oncology®
Hepatocellular Carcinoma: Examining Its Prevalence and Prognostic Biomarkers
Hepatocellular Carcinoma: Reducing Barriers in Diagnosis and Treatment
Hepatocellular Carcinoma: Reducing Barriers in Diagnosis and Treatment
Project Oncology®
Hepatocellular Carcinoma: Reducing Barriers in Diagnosis and Treatment
Optimizing Treatment of Metastatic G/GEJ Cancers: Balancing Efficacy and Adverse Effects With Combination Regimens
Optimizing Treatment of Metastatic G/GEJ Cancers: Balancing Efficacy and Adverse Effects With Combination Regimens
MinuteCE®
Optimizing Treatment of Metastatic G/GEJ Cancers: Balancing Efficacy and Adverse Effects With Combination Regimens
1.25 program credits
- Yelena Janjigian, MD
- Samuel J. Klempner, MD
1.25 program credits
Integrating Clinical Insights: Key G/GEJ Cancer Data Analyzed from the San Diego Oncology Conference
Integrating Clinical Insights: Key G/GEJ Cancer Data Analyzed from the San Diego Oncology Conference
MinuteCE®
Integrating Clinical Insights: Key G/GEJ Cancer Data Analyzed from the San Diego Oncology Conference
1.25 program credits
- Samuel J. Klempner, MD
1.25 program credits
How Can a Multidisciplinary Team Optimize Management of G/GEJ Cancer–Related Symptom Burden?
How Can a Multidisciplinary Team Optimize Management of G/GEJ Cancer–Related Symptom Burden?
MinuteCE®
How Can a Multidisciplinary Team Optimize Management of G/GEJ Cancer–Related Symptom Burden?
1.25 program credits
- Yelena Janjigian, MD
1.25 program credits
Navigating Treatment Paths: Selection and Sequencing in Biomarker-Driven Combination Regimens for First-Line G/GEJ Cancer Therapy
Navigating Treatment Paths: Selection and Sequencing in Biomarker-Driven Combination Regimens for First-Line G/GEJ Cancer Therapy
MinuteCE®
Navigating Treatment Paths: Selection and Sequencing in Biomarker-Driven Combination Regimens for First-Line G/GEJ Cancer Therapy
1.25 program credits
- Yelena Janjigian, MD
- Samuel J. Klempner, MD
1.25 program credits
HER2 & PD-L1: Exploring Clinical Characteristics of G/GEJ Cancers in Relation to Biomarker Positivity
HER2 & PD-L1: Exploring Clinical Characteristics of G/GEJ Cancers in Relation to Biomarker Positivity
MinuteCE®
HER2 & PD-L1: Exploring Clinical Characteristics of G/GEJ Cancers in Relation to Biomarker Positivity
1.25 program credits
- Yelena Janjigian, MD
1.25 program credits
Claudin18.2: An Emerging Biomarker and Its Significance as a Therapeutic Target in G/GEJ Cancers
Claudin18.2: An Emerging Biomarker and Its Significance as a Therapeutic Target in G/GEJ Cancers
MinuteCE®
Claudin18.2: An Emerging Biomarker and Its Significance as a Therapeutic Target in G/GEJ Cancers
1.25 program credits
- Samuel J. Klempner, MD
1.25 program credits
Incorporating Data Into Practice: Late-Breaking Highlights on G/GEJ Cancers From the 2024 GI Congress
Incorporating Data Into Practice: Late-Breaking Highlights on G/GEJ Cancers From the 2024 GI Congress
MinuteCE®
Incorporating Data Into Practice: Late-Breaking Highlights on G/GEJ Cancers From the 2024 GI Congress
1.25 program credits
- Yelena Janjigian, MD
1.25 program credits